Create knowledge
[?]
|
(rate this)
|
The report 'Booming Biotechnology Market in India' by RNCOS provides an exhaustive overview of the biotechnology market in India. It provides a detailed account of the factors that define the structure and composition of the Indian biotechnology market, making it one of the world's most potential markets. The report provides comprehensive information on the market size, structure, domestic consumption, exports, key segments, investment, manpower, market share of key players, drivers, restraints and present and future trends of the biotechnology market in India. The research findings help identify the difference between the biotechnology market in India and the US and European markets in ter...
 |
sweena makhija
| Commented
| 2 years ago
|
|
The Biotech industry may be booming but the trained manpower in the field is multiplying at an even faster rate. clearly government should be taking better targeted and more frequent initiatives in the sector which is designing the future in a...
|
|
 |
Durgesh Yadav
| Commented
| 3 years ago
|
|
The more so importance of India in the field of Biotechnology is huge actually. In addition to generating trained manpower and a knowledge base, India is proving to be an ideal setting for manufacturing activites and high-level biotechnology research...
|
|
 |
BEENA AGARWAL
| Commented
| 3 years ago
|
|
Nice analysis.Also I agree with Durgesh too as India has got supreme manpower in very nominal price and intelligent brain with comparison to rest of the world.Also people here are ambitious and hardworking, if one provide facilities our researches...
|
|
Trends: "Booming Biotech Market in India" deleted from your view.
|
(rate this)
|
Biotech industry business models have been evolving to product-centered strategies with shorter periods to return on invested capital. 'We're seeing a shift from technology-based to product-based companies. Specifically, we're seeing a shift toward drugs as the driver of value, i.e., clinical compounds as opposed to technologies which focused on the upstream processes of drug discovery. The time from the use of these technologies to getting a drug on the market is so long and that protracted time frame -- 10+ years -- limits what pharmaceutical companies and investors are willing to pay for them,' a senior-level VC points out. 'The focus instead is on nearer term profits. Money invested in ...
|
|
mukesh mehta
| Commented
| 3 years ago
|
|
Sir/Madam, We at Zeopane have developed a new and innovative drug-delivery technology called zeolite micro-needles that is superior to the conventional technologies being used currently. Micro-needles are believed to be the drug-delivery mechanism...
|
|
Trends: "Trends in biotechnology " deleted from your view.
|
(rate this)
|
|
|
Sriram Parameswaran
| Answered
| 3 years ago
|
|
According to all present theories NO; unless of course one considers the very very very remote possibility of horizontal transfer of genes from plant- bacteria- your gut cells. The chance is really remote and 99.99% of the DNA that encodes the...
|
|
|
|
Durgesh Yadav
| Answered
| 3 years ago
|
|
No. There is no relationship between an antibiotic-resistance marker gene used in plants and antibiotic resistance in humans. The marker gene is used in research to help researchers distinguish a new plant variety from related plants. When the...
|
|
Answer: "Will antibiotic-resistance marker genes make me resistant to the target antibiotics?" deleted from your view.
|
(rate this)
|
 |
Bindu Narayan
| Answered
| 3 years ago
|
|
This is a billion $ question you have raised. My personal opinion on the same is that, core research or cutting edge research is never performed in the industry (biotech and pharma included). core research is always performed at the leading...
|
|
Answer: "What is the scope of Biotechnology start-ups and research in India? Which companies in US and Europe collabrates with..." deleted from your view.
|
(rate this)
|
Nowadays biotech companies are facing many problems such as accessing sufficient capital, wisely allocating constrained resources, developing and executing beneficially designed collaborations and partnerships, demonstrating the courage to make difficult, sometimes complex, go/no-go decisions, making appropriate risk assessment and effectively managing assets. Also there is goal and objective revision , and you have to keep coming up with new ideas and then framing them into fully functional products. Here we will focus on manging the greatest assets of firm i.e people and you have to be careful about the M A 's happening and risk of product failures. Sometimes in start up companies a proj...
Trends: "Managing Changes in biotech firms " deleted from your view.
Follow me on
